MEWS ER
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
Genelux (NASDAQ: GNLX) reported its Q2 2024 financial results and provided business updates. The company completed a $30 million public offering, providing runway through three trial readouts. Genelux anticipates interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025 and interim data from the Phase 1b trial in recurrent small cell lung cancer later this year. The ongoing Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer continues enrollment with topline results expected in H2 2025.
Financial highlights include:
Cash, cash equivalents, and investments of $40.4 million as of June 30, 2024
R&D expenses increased to $4.4 million in Q2 2024
G&A expenses remained flat at $2.5 million
Net loss of $6.6 million or $0.22 per share
Genelux (NASDAQ: GNLX) reported its Q2 2024 financial results and provided business updates. The company completed a $30 million public offering, providing runway through three trial readouts. Genelux anticipates interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025 and interim data from the Phase 1b trial in recurrent small cell lung cancer later this year. The ongoing Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer continues enrollment with topline results expected in H2 2025.
Financial highlights include:
Cash, cash equivalents, and investments of $40.4 million as of June 30, 2024
R&D expenses increased to $4.4 million in Q2 2024
G&A expenses remained flat at $2.5 million
Net loss of $6.6 million or $0.22 per share
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2545Followers
107Following
28KVisitors
Follow